About TissueGene
TissueGene is a company based in Rockville (United States) founded in 1999.. TissueGene has raised $94.64 million across 4 funding rounds from investors including Maryland Stem Cell Research Fund. The company has 29 employees as of December 31, 2022. TissueGene offers products and services including TG-C. TissueGene operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Rockville, United States
- Employees 29 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Kolon Tissuegene, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$94.64 M (USD)
in 4 rounds
-
Latest Funding Round
$35 M (USD), Series C
May 23, 2024
- Investors
-
Employee Count
29
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TissueGene
TissueGene offers a comprehensive portfolio of products and services, including TG-C. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats osteoarthritis by reducing pain and improving knee function.
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Senior Team
1 people
Finance and Accounting
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of TissueGene
TissueGene has successfully raised a total of $94.64M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $35 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $35.0M
-
First Round
First Round
(30 Jun 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series C - TissueGene | Valuation |
investors |
|
| May, 2023 | Amount | Series B - TissueGene | Valuation |
investors |
|
| Aug, 2022 | Amount | Series B - TissueGene | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TissueGene
TissueGene has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Maryland Stem Cell Research Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stem cell research startups in healthcare are funded and accelerated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TissueGene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TissueGene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tissuegene Comparisons
Competitors of TissueGene
TissueGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tissuegene
Frequently Asked Questions about TissueGene
When was TissueGene founded?
TissueGene was founded in 1999 and raised its 1st funding round 18 years after it was founded.
Where is TissueGene located?
TissueGene is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of TissueGene?
Moon Noh is the current CEO of TissueGene.
Is TissueGene a funded company?
TissueGene is a funded company, having raised a total of $94.64M across 4 funding rounds to date. The company's 1st funding round was a Series B of $29.64M, raised on Jun 30, 2017.
How many employees does TissueGene have?
As of Dec 31, 2022, the latest employee count at TissueGene is 29.
What does TissueGene do?
Founded in 1999 and based in Rockville, United States, TissueGene operates in the biotechnology sector, focusing on allogeneic cell therapies for orthopedic conditions. The lead product, TG-C, is advanced to phase III trials for cartilage regeneration in severe knee osteoarthritis through engineered human chondrocytes producing TGF-β1. Preclinical efforts target bone, disc, and nerve regeneration.
Who are the top competitors of TissueGene?
TissueGene's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does TissueGene offer?
TissueGene offers TG-C.
Who are TissueGene's investors?
TissueGene has 1 investor. Key investors include Maryland Stem Cell Research Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.